Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In an effort to rein in costs and galvanize its discovery effort, Merck is following the industry vogue for externalizing early-stage R&D. Is it going to cast its net far and wide enough?
Bispecifics by orthogonal interfaces To improve correct antibody heavy-light chain pairing during bispecific antibody assembly, Lewis et al. design antibody heavy and light chains with orthogonal interfaces.
Emerging technologies are broadening our understanding of the human immune system, but capitalizing on their application will likely require philosophical and practical changes to the way research is done.